The latest report by IMARC Group, titled "Europe Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," finds that the Europe idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 8.3% during 2023-2028. Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial pneumonia that severely impacts the functioning of the lungs. It forms scar tissue within the lungs that starts at the edges and develops toward the center, thus causing insufficient oxygen delivery to body parts. It is diagnosed through various chest imaging studies, including pulmonary function tests, lung biopsies, and antibody tests. Moreover, this condition is treated with antifibrotic therapies, including nintedanib and pirfenidone-based drugs, that improve lung functioning and minimize the risks of respiratory deterioration. In recent years, there has been an escalating demand for IPF treatment procedures due to the growing prevalence of lung disorders.
Europe Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The market is primarily driven by the growing prevalence of chronic lung and fibrotic diseases in Europe. In addition, the growing geriatric population that is more susceptible to such ailments represents another major growth-inducing factor. Besides this, the changing living standards, high smoking rates, and increasing environmental pollutants are causing various lung diseases among individuals. This, coupled with the increasing health consciousness and growing awareness regarding the presence of effective IPF preventive and management treatment, is positively influencing the market growth. Moreover, the market is further propelled by the increasing government investments in developing existing healthcare systems. Furthermore, rapid advancements in diagnostic techniques and research and development (R&D) activities conducted by the leading players for introducing novel medicines are also creating a positive market outlook across the region.
- Based on the drug class, the market has been categorized into MAPK, tyrosine, and autotaxin inhibitors.
- On the basis of end user, the market has been classified into hospitals, long-term care facilities, and others.
- On the geographical front, the market has been divided into Germany, France, the United Kingdom, Italy, Spain, and others.
- The competitive landscape of the market has been examined in the report, along with detailed profiles of the key players operating in the industry.
|Base Year of the Analysis
||Drug Class, End User, Country
||Germany, France, United Kingdom, Italy, Spain, Others
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N A
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800